- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04293523
Une étude de 48 mois pour évaluer l'efficacité à long terme d'Eocta sur la santé des articulations (A-MORE)
Une étude observationnelle multicentrique de 48 mois pour évaluer l'efficacité à long terme d'Eocta sur la santé des articulations
This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.
Aperçu de l'étude
Description détaillée
Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.
Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.
The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne
- Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
-
Bonn, Allemagne
- Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
Frankfurt, Allemagne
- Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
-
Frankfurt, Allemagne
- Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
-
Hamburg, Allemagne
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Hanover, Allemagne
- Medizinische Hochschule Hannover
-
Hanover, Allemagne
- Werlhof-Institut für Hämostaseologie GmbH
-
Heidelberg, Allemagne
- SRH-Klinikum Heidelberg
-
Mörfelden-Walldorf, Allemagne
- HZRM Hämöphilie Zentrum Rhein Main
-
München, Allemagne
- Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
-
-
-
-
-
Riyadh, Arabie Saoudite
- Dr Suliman Al Habib Hospital Riyadh
-
Riyadh, Arabie Saoudite
- King Faisal Specialised Hospital, KFSH Riyadh, Children
-
Riyadh, Arabie Saoudite
- King Faisal Specialist Hospital KFSH, Adults
-
Riyadh, Arabie Saoudite
- Riyadh Military Hospital (P.S.M.C)
-
-
-
-
-
Barcelona, Espagne
- Sant Johan De Deu
-
Barcelona, Espagne
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Espagne
- Hospital Vall d'Hebron
-
Cruces, Espagne
- Hospital Universitario Cruces
-
Donostia / San Sebastian, Espagne
- Hospital Universitario Donostia
-
Murcia, Espagne
- Hospital Virgen de la Arrixaca
-
Málaga, Espagne
- Hospital Universitario Carlos Haya
-
Navarro, Espagne
- Complejo Hospitalario de Navarra
-
Oviedo, Espagne
- Hospital Universitario Central de Asturias (HUCA)
-
Palma de Mallorca, Espagne
- Hospital Universitario Son Espases
-
Seville, Espagne
- Hospital Universitario Virgen del Rocío
-
Vigo, Espagne
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Tallinn, Estonie
- Lastehaigla, Tallinn (Tallinn Children´s Hospital)
-
Tallinn, Estonie
- The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
-
-
-
-
-
Helsinki, Finlande
- Helsinki University Central Hospital, New Children Hospital
-
Turku, Finlande
- Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
-
-
-
-
-
Thessaloniki, Grèce
- Ippokrateio Hospital Thessaloniki (adult department)
-
Thessaloniki, Grèce
- Ippokrateio Hospital Thessaloniki (pediatric department)
-
-
-
-
-
Bari, Italie
- University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
-
Cesena, Italie
- AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
-
Genova, Italie
- Giannina Gaslini Institute
-
Milan, Italie
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Parma, Italie
- University Hospital of Parma, AOUP, Haemophilia Center
-
Rome, Italie
- Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
-
Torino, Italie
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
-
-
-
-
-
Muscat, Oman
- The Royal Hospital
-
-
-
-
-
Groningen, Pays-Bas
- University Medical Center Groningen/UMCG
-
-
-
-
-
Canterbury, Royaume-Uni
- East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
-
London, Royaume-Uni
- Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
-
-
-
-
-
Ljubljana, Slovénie
- University Medical Centre Ljubljana Division of Paediatrics
-
-
-
-
-
Bern, Suisse
- Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
-
Lausanne, Suisse
- Service et Laboratoire central d'hématologie, Adults
-
Sankt Gallen, Suisse
- Zentrum für Labormedizin
-
Zurich, Suisse
- Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
-
-
-
-
-
Gothenburg, Suède
- Hematologimottagning Sahlgrenska
-
Malmö, Suède
- Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
-
-
-
-
-
Brno, Tchéquie
- University Hospital Brno
-
Ostrava, Tchéquie
- University Hospital Ostrava
-
Prague, Tchéquie
- Dept. of Pediatric Haematology and Oncology, University Hospital Motol
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.
La description
Inclusion Criteria:
- Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
- Have a diagnosis of haemophilia A
- At enrolment on prophylactic treatment with Elocta, independent of participation in the study
Exclusion Criteria:
- Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
- Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Hemophilia A patients
All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice. |
Extended half-life factor VIII product
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Joint health: Target joint development
Délai: 48 months
|
Number of target joints |
48 months
|
|
Joint health: Target joint resolution
Délai: 48 months
|
Number of resolved target joints |
48 months
|
|
Joint health: Target joint recurrence
Délai: 48 months
|
Number of recurring target joints |
48 months
|
|
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Délai: 48 months
|
Number of joint bleeding events per year, for treated bleeds |
48 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Délai: 48 months
|
The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome. |
48 months
|
|
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Délai: 48 months
|
The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles. The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome. |
48 months
|
|
Joint and physical evaluation for elbows, knees and ankles.
Délai: 48 months
|
The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome. |
48 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Délai: 48 months
|
Number of bleeding events per year, for treated bleeds |
48 months
|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Délai: 48 months
|
Number of bleeding events per year, for all bleeds |
48 months
|
|
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Délai: 48 months
|
Percentage (%) of study population with zero (0) joint bleeds |
48 months
|
|
Effectiveness of Elocta: Work productivity and impairment
Délai: 48 months
|
Assessed by WPAI-SHP questionnaire |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Délai: 48 months
|
Assessed by Haemo-QoL/Haem-A-QoL questionnaire |
48 months
|
|
Effectiveness of Elocta: Physical activity level
Délai: 48 months
|
Assessed by the Saltin-Grimby scale |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Délai: 48 months
|
Assessed by EQ-5D-5L/EQ-5D-Y questionnaire |
48 months
|
|
Effectiveness of Elocta: Severity of joint health
Délai: 48 months
|
Assessed by Patient Global Impression of Severity of Joint Health questionnaire |
48 months
|
|
Effectiveness of Elocta: FVIII plasma levels
Délai: 48 months
|
Percentage (%) of FVIII plasma level |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Délai: 48 months
|
Assessed by medication dose |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Délai: 48 months
|
Assessed by total number of exposure days per medication |
48 months
|
|
Usage of Elocta: Annualised injection frequency per subject
Délai: 48 months
|
Assessed by prescription |
48 months
|
|
Usage of Elocta: Annualised factor consumption per subject
Délai: 48 months
|
Assessed by prescription [IU/kg] |
48 months
|
|
Usage of Elocta: Adherence
Délai: 48 months
|
Investigator assessed (Percentage (%)) |
48 months
|
|
Exploratory Objective
Délai: 48 months
|
Influence of different Elocta prophylaxis regimens on long term joint health |
48 months
|
|
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Délai: 48 months
|
Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level |
48 months
|
|
Exploratory Objective: Explore adherence to prescribed treatment regimen
Délai: 48 months
|
florio HAEMO captured treatment adherence scores |
48 months
|
|
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Délai: 48 months
|
florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps) |
48 months
|
|
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Délai: 48 months
|
florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels |
48 months
|
|
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Délai: 48 months
|
florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Target joint development, resolution and recurrence |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Annualised joint bleeding rate (AJBR) for treated bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Ultrasound (HEAD-US) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Clinical joint scoring (HJHS) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Occurrence of zero (0) joint bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Quality of Life assessed by Haemo-QoL/Haem-A-QoL |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Délai: 48 months
|
Physical activity level assessed by the Saltin-Grimby scale |
48 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Study Physician, Swedish Orphan Biovitrum
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies génétiques, innées
- Maladies hématologiques
- Troubles de la coagulation sanguine
- Troubles hémorragiques
- Troubles de la coagulation sanguine, héréditaires
- Troubles des protéines de la coagulation
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies hémiques et lymphatiques
- Hémophilie A
- protéine de fusion facteur VIII-Fc
Autres numéros d'identification d'étude
- Sobi.Elocta-005
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .